Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

VVOS vs ENSC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ENSC Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–3 Matrix Metrics)

ENSC Overall Winner 6-Pillar Tally: VVOS 2 – 3 ENSC (1 Tie) Matrix Metrics: VVOS 3 – 6 ENSC

As of Nov 20, 2026, Ensysce Biosciences, Inc. (ENSC) is the stronger overall head-to-head candidate over Vivos Therapeutics, Inc. (VVOS) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). VVOS carries a Unified Composite Score of 36.4/100 (SELL) at $0.05 (N/M Forward P/E, -107.9% operating margin), whereas ENSC carries 53.4/100 (HOLD) at $0.36 (0.8x Forward P/E, -281.3% operating margin).

  • Growth vs. Quality Trade-Off: ENSC earns the overall head-to-head edge with a stronger Unified Composite Score (53.4/100 HOLD vs. VVOS 36.4/100 SELL) and 0.98β · 79% Vol risk profile, whereas VVOS leads top-line expansion (+34.9% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: VVOS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 18.9); meanwhile ENSC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VVOS vs ENSC
VVOS NASDAQ
Vivos Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.05
-5.1% 1D
Market Cap $1.9M
TTM Revenue $21M
Forward P/E N/M
Beta / 30D Vol 1.70β · 111% Vol
Unified Composite Score
36.4 / 100 SELL
Tech 25.0 Fund 35.0 Flow 50.0 Mom 30.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -29.8%), weak momentum, RSI 19
RSI-14: 18.9 · SMA20: $0.10 · SMA50: $0.13
ENSC NASDAQ Head-to-Head Winner
Ensysce Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$0.36
-0.17% 1D
Market Cap $7.0M
TTM Revenue $4.5M
Forward P/E 0.8x
Beta / 30D Vol 0.98β · 79% Vol
Unified Composite Score
53.4 / 100 HOLD
Tech 50.0 Fund 62.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -2.4%), weak momentum, RSI 40
RSI-14: 39.7 · SMA20: $0.39 · SMA50: $0.44

6-Pillar Scorecard Institutional Category Breakdown (VVOS 2 – 3 ENSC)

Columns: Metric · VVOS · ENSC
1. Valuation Multiples ENSC
Forward P/E N/M 0.8x
Trailing P/E N/M 0.8x
PEG Ratio N/M N/M
EV / Revenue 0.1x 1.4x
2. Growth & Scale VVOS
Revenue Growth (YoY) +34.9% -15.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $21M $4.5M
Market Cap $1.9M $7.0M
3. Profitability & Quality VVOS
Gross Margin 61.9% N/A
Operating Margin -107.9% -281.3%
Net Profit Margin -121.8% -280.5%
Return on Equity (ROE) -8585.3% -1295.1%
4. Balance Sheet & Cash Flow ENSC
Cash Generation (TTM) -$21M EBITDA -$9.7M
Cash Flow Margin -99.3% EBITDA Mgn N/A
Net Cash / Leverage -8585.3% ROE -$499,633 Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ENSC
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VVOS (3) vs ENSC (6)
Institutional Metric VVOS ENSC Criterion Row Edge
Market Capitalization
Scale
$1.9M $7.0M Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M 0.8x Lower Multiple ENSC
Forward P/E Ratio
Valuation
N/M 0.8x Lower Multiple ENSC
Revenue Growth (YoY)
Growth
+34.9% -15.1% Higher Growth VVOS
Operating Margin (TTM)
Profitability
-107.9% -281.3% Higher Margin VVOS
Net Profit Margin
Profitability
-121.8% -280.5% Higher Margin VVOS
Return on Equity (ROE)
Capital Efficiency
-8585.3% -1295.1% Higher ROE ENSC
52-Week Range Position
Momentum
0% ($0–$3) 8% ($0–$2) Stronger Trend ENSC
Beta / 30D Volatility
Risk Regime
1.70β · 111% Vol 0.98β · 79% Vol Lower Realized Risk ENSC
Unified Institutional Score
Composite Signal
36.4 / 100 (SELL) 53.4 / 100 (HOLD) Higher Composite ENSC
Trailing 12M Revenue (USD)
Operating Scale
$21M $4.5M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
61.9% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.1x EV/Rev N/M PEG · 1.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$21M EBITDA (-8585.3% ROE) -$9.7M (-$499,633 Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ENSC +29.7 pp
VVOS: -59.25% · ENSC: -29.55%
3M Horizon ENSC +80.21 pp
VVOS: -80.49% · ENSC: -0.28%
6M Horizon ENSC +104.14 pp
VVOS: -91.15% · ENSC: +12.99%
1Y Horizon ENSC +17.38 pp
VVOS: -97.71% · ENSC: -80.33%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period VVOS Revenue ENSC Revenue VVOS Op. Margin ENSC Op. Margin Margin Leader
FY2019 $10M N/A -92.8% N/A VVOS
FY2020 $10M $0M -92.1% -41.0% ENSC
FY2021 $20M $0M -120.7% -562.7% VVOS
FY2022 $20M $0M -156.2% -959.9% VVOS
FY2023 $10M $0M -125.3% -480.5% VVOS
FY2024 $20M $10M -74.3% -129.2% VVOS
FY2025 $20M $10M -114.1% -202.1% VVOS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VVOS BREAKDOWN
113d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VVOS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ENSC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ENSC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VVOS Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $1.9M market capitalization and -107.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ENSC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $7.0M market capitalization and -281.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VVOS vs ENSC Key Questions & Quantitative Answers

As of Nov 20, 2026, Ensysce Biosciences, Inc. (ENSC) is the stronger overall head-to-head candidate over Vivos Therapeutics, Inc. (VVOS) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). VVOS carries a Unified Composite Score of 36.4/100 (SELL) at $0.05 (N/M Forward P/E, -107.9% operating margin), whereas ENSC carries 53.4/100 (HOLD) at $0.36 (0.8x Forward P/E, -281.3% operating margin). Growth vs. Quality Trade-Off: ENSC earns the overall head-to-head edge with a stronger Unified Composite Score (53.4/100 HOLD vs. VVOS 36.4/100 SELL) and 0.98β · 79% Vol risk profile, whereas VVOS leads top-line expansion (+34.9% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: VVOS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 18.9); meanwhile ENSC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VVOS leads the Growth & Scale pillar: VVOS posts +34.9% YoY revenue growth and +0.0% YoY earnings growth on $21M TTM revenue (61.9% gross margin, -107.9% operating margin), compared with ENSC at -15.1% YoY revenue growth and +0.0% YoY earnings growth on $4.5M TTM revenue (N/A gross margin, -281.3% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), VVOS cumulative revenue shifted +100.0% while ENSC shifted +0.0%. In operating R&D and SG&A reinvestment, VVOS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ENSC.

ENSC screens cheaper on headline valuation multiples. VVOS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-99.3% EBITDA margin), whereas ENSC trades at 0.8x Forward P/E, 0.8x Trailing P/E, N/M PEG, and 1.4x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VVOS (-8585.3% ROE) versus ENSC (-1295.1% ROE) capital efficiency.

In options market volatility and institutional positioning, VVOS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.70β · 111% Vol realized risk). By comparison, ENSC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.98β · 79% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.